EUVIMEDEUVIMED entdecken
Editorial

The end of the primary–secondary prevention dichotomy in high-risk diabetes? Lessons from VESALIUS-CV

Salvatore Corrao, Massimo Federici

Acta Diabetologica · 2026

DOI: 10.1007/s00592-026-02748-8 ↗

Kurz gefasst

Editorial in der Zeitschrift Acta Diabetologica, 2026. Verfasst von Salvatore Corrao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy. sa…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Secondary Prevention. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The VESALIUS-CV trial was the first dedicated cardiovascular-outcomes study to demonstrate that adding the PCSK9 inhibitor evolocumab to statin therapy prevents a first major cardiovascular event in patients without a previous myocardial infarction or stroke. A prespecified analysis extended this benefit to patients with diabetes and no known significant atherosclerosis, in whom intensive low-density lipoprotein cholesterol (LDL-C) lowering reduced major adverse cardiovascular events by approximately one third. These findings challenge the long-standing reliance on the primary-secondary prevention distinction to determine the intensity of lipid-lowering therapy. We argue that in high-risk diabetes-a systemic immunometabolic syndrome characterised by adiposopathy, insulin resistance, chronic inflammation and atherogenic dyslipidaemia-the arterial wall is biologically diseased long before a first clinical event. Cardiovascular prevention in this population should therefore move from an event-based to a biology-based paradigm, governed by biological risk rather than by event history.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Secondary PreventionHumansAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPrimary PreventionClinical Trials as Topic

Stichwörter der Autor:innen

AdiposopathyCardiovascular preventionEvolocumabLDL cholesterolPCSK9 inhibitionPrimary preventionType 2 diabetesVESALIUS-CV

Substanzen

Antibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLevolocumabHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 Inhibitors

Autor:innen und Institutionen

  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy. salvatore.corrao@unipa.it.
  • Department of Clinical Medicine, Unit of Internal Medicine, Civico Hospital, ARNAS Civico Di Cristina e Benfratelli, Piazza Nicola Leotta 4, Palermo, 90127, Italy. salvatore.corrao@unipa.it.
  • Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
  • IRCCS Neuromed, Pozzilli, IS, Italy.

Zitieren

APA

Corrao, S., & Federici, M. (2026). The end of the primary–secondary prevention dichotomy in high-risk diabetes? Lessons from VESALIUS-CV. Acta Diabetologica. https://doi.org/10.1007/s00592-026-02748-8

Vancouver

Corrao S, Federici M. The end of the primary–secondary prevention dichotomy in high-risk diabetes? Lessons from VESALIUS-CV. Acta Diabetologica. 2026. doi:10.1007/s00592-026-02748-8

BibTeX
@article{Corrao2026,
  author = {Corrao, Salvatore and Federici, Massimo},
  title = {The end of the primary–secondary prevention dichotomy in high-risk diabetes? Lessons from VESALIUS-CV},
  journal = {Acta Diabetologica},
  year = {2026},
  doi = {10.1007/s00592-026-02748-8}
}
Kostenlos starten →